Vai offline con l'app Player FM !
Antibody-Drug Conjugate “Promising Efficacy” in HER2-Positive and HER2-Low Breast Cancer
Manage episode 450415478 series 1021077
In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.”
At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in patients treated with the ADC. Oncology Times correspondent Peter Goodwin talked with Christina Teng, PhD, the presenting author of the new research from Scientia Clinical Research and the Prince of Wales Hospital in Sydney, Australia.
179 episodi
Manage episode 450415478 series 1021077
In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.”
At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in patients treated with the ADC. Oncology Times correspondent Peter Goodwin talked with Christina Teng, PhD, the presenting author of the new research from Scientia Clinical Research and the Prince of Wales Hospital in Sydney, Australia.
179 episodi
모든 에피소드
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.